A Phase II randomized multicenter study to assess the efficacy of lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor in patients with low and intermediate-1 risk myelodysplastic syndrome.

Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2009
This article has no abstract
Epistemonikos ID: 0e04c24828e5388efb250f0c8db3989722d02f5e
First added on: Apr 16, 2025